DK1294382T3 - 7-hydroxy-epiandrosteron med neuroprotektiv aktivitet - Google Patents

7-hydroxy-epiandrosteron med neuroprotektiv aktivitet

Info

Publication number
DK1294382T3
DK1294382T3 DK01945494T DK01945494T DK1294382T3 DK 1294382 T3 DK1294382 T3 DK 1294382T3 DK 01945494 T DK01945494 T DK 01945494T DK 01945494 T DK01945494 T DK 01945494T DK 1294382 T3 DK1294382 T3 DK 1294382T3
Authority
DK
Denmark
Prior art keywords
hydroxy
epiandrosterone
neuroprotective activity
steroids
neuroprotective
Prior art date
Application number
DK01945494T
Other languages
Danish (da)
English (en)
Inventor
Ernst Wuelfert
Ashley Ker Pringle
Lars Eric Sundstrom
Original Assignee
Hunter Fleming Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hunter Fleming Ltd filed Critical Hunter Fleming Ltd
Application granted granted Critical
Publication of DK1294382T3 publication Critical patent/DK1294382T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK01945494T 2000-06-29 2001-06-29 7-hydroxy-epiandrosteron med neuroprotektiv aktivitet DK1294382T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0016022A GB2363983A (en) 2000-06-29 2000-06-29 Protection against neuronal damage using 7-hydroxyepiandrosterone
PCT/GB2001/002937 WO2002000225A1 (fr) 2000-06-29 2001-06-29 7-hydroepiandrosterone presentant une activite neuroprotectrice

Publications (1)

Publication Number Publication Date
DK1294382T3 true DK1294382T3 (da) 2008-11-24

Family

ID=9894707

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01945494T DK1294382T3 (da) 2000-06-29 2001-06-29 7-hydroxy-epiandrosteron med neuroprotektiv aktivitet

Country Status (24)

Country Link
US (2) US7718639B2 (fr)
EP (1) EP1294382B1 (fr)
JP (1) JP4942905B2 (fr)
KR (1) KR100786284B1 (fr)
CN (1) CN100459980C (fr)
AT (1) ATE401897T1 (fr)
AU (2) AU6770901A (fr)
CA (1) CA2414584C (fr)
CY (1) CY1108773T1 (fr)
CZ (1) CZ299676B6 (fr)
DE (1) DE60134979D1 (fr)
DK (1) DK1294382T3 (fr)
ES (1) ES2310182T3 (fr)
GB (1) GB2363983A (fr)
HK (1) HK1052300B (fr)
HU (1) HU227152B1 (fr)
IL (2) IL153541A0 (fr)
NO (1) NO327959B1 (fr)
PL (1) PL200699B1 (fr)
PT (1) PT1294382E (fr)
RU (1) RU2307654C2 (fr)
SI (1) SI1294382T1 (fr)
WO (1) WO2002000225A1 (fr)
ZA (1) ZA200300085B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
GB2378898A (en) * 2001-08-14 2003-02-26 Hunter Fleming Ltd Prophylactic and therapeutic use of hydroxysteroids
JP2006506445A (ja) * 2002-08-28 2006-02-23 ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド 治療処置の方法
GB0409498D0 (en) * 2004-04-28 2004-06-02 Hunter Fleming Ltd Transdermal steroid formulation
MX2009005335A (es) * 2006-11-21 2009-06-08 Umecrine Ab El uso de esteroides de pregnano y androstano para la fabricacion de una composicion farmaceutica para el tratamiento de trastornos del snc.
GB0623971D0 (en) * 2006-11-30 2007-01-10 Hunter Fleming Ltd Modulation of prostaglandin/cyclooxygenase metabolic pathways
HRP20120687T1 (hr) 2006-11-30 2012-09-30 Hunter-Fleming Limited Moduliranje metabolizma prostaglandina/ciklooksigenaze

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU243975A (en) 1974-10-14 1982-06-30 Schering Ag Process for obtaining 7-hydroxyestradiols
US5707983A (en) 1990-08-29 1998-01-13 Humanetics Corporation Treatment of alzheimer's disease and modulation of immune system with Δ5-androstenes
US5292730A (en) * 1990-08-29 1994-03-08 Humanetics Corporation Modulation of immune system with Δ5-androstenes
US5212167A (en) * 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
FR2696934B1 (fr) * 1992-10-20 1995-06-02 Conservatoire Nal Arts Metiers Dérivés de stéroïdes naturels 3B hydroxyles ayant des propriétés de déclenchement et de stimulation de l'immunité, composition les contenant et procédé pour les obtenir.
SK103195A3 (en) 1993-03-09 1996-12-04 Univ Utah Res Found Use of dehydroepiandrosterone derivative for pharmaceutical compositions production and pharmaceutical composition containing dehydroepiandrosterone derivative
US5846963A (en) 1995-06-07 1998-12-08 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US5387583A (en) * 1993-04-20 1995-02-07 Loria; Roger M. Compositions containing corticosteroids or analogues thereof and corticosteroid buffering effective amounts of 5-androstene 3B, 17B or 5-androstene 3B, 7B, 17B triol or analogues thereof
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5877169A (en) 1993-11-05 1999-03-02 University Of Florida Research Foundation, Inc. Methods of treatment of ischemic damage
US5976850A (en) 1994-10-19 1999-11-02 University Of Edinburgh Hippocampus-associated proteins; DNA sequences coding therefor and uses thereof
US5556847A (en) * 1994-10-27 1996-09-17 Duquesne University Of The Holy Ghost Methods of effecting memory enhancement mediated by steroid sulfatase inhibitors
EP1288220A3 (fr) 1995-06-06 2004-07-21 Euro-Celtique Dérivés neuroactifs 3.alpha.-Hydroxy-Andsrostanes et -Pregnanes
EP0840612A1 (fr) 1995-07-24 1998-05-13 Trustees Of Boston University Inhibition de l'activite des recepteurs du n-methyl-d-aspartate au moyen de derives de sulfate de pregnenolone
GB2317826B (en) * 1995-08-29 1999-12-15 Univ Edinburgh Regulation of intracellular glucocorticoid concentrations
US5985242A (en) 1995-10-27 1999-11-16 Praecis Pharmaceuticals, Inc. Modulators of β-amyloid peptide aggregation comprising D-amino acids
NZ331975A (en) * 1996-04-09 2000-12-22 Btg Int Ltd Use of 7 alpha-substituted steroids to treat neuropsychriatic disorders or enhance cognition
CA2262453A1 (fr) 1996-08-27 1998-03-05 Praecis Pharmaceuticals Incorporated Modulateurs de l'agregation de peptides beta-amyloides, comprenant des d-aminoacides
FR2760362B1 (fr) 1997-03-10 2000-08-11 Vitasterol Utilisation cosmetique ou dermatologique de steroides 7-hydroxyles
WO1998043647A1 (fr) 1997-03-28 1998-10-08 Massachusetts Institute Of Technology, Inc. Regulation de l'expression de la proteine precurseur amyloide (app) au moyen de composes oestrogeniques
GB9708716D0 (en) * 1997-04-29 1997-06-18 Imperial College Chronic heart failure
US6544972B1 (en) * 1997-09-25 2003-04-08 Regents Of The University Of Minnesota Methods of limiting apoptosis of cells
WO1999024400A1 (fr) 1997-11-10 1999-05-20 Vyrex Corporation Esters de probucol et leurs utilisations
JP2004515446A (ja) * 1997-11-24 2004-05-27 ユニバーシティ・オブ・フロリダ・リサーチ・ファンデーション・インコーポレーテッド テストステロン阻害剤及びニューロンの保護のためのその用途
GB9726569D0 (en) 1997-12-16 1998-02-11 Univ Southampton Neuroprotective agents
WO1999052532A1 (fr) * 1998-04-14 1999-10-21 Pharmadigm, Inc. Procede permettant de reduire la deterioration du systeme nerveux central
FR2786102B1 (fr) 1998-11-20 2001-02-16 Monique Vincens Utilisation de sulfate de dehydroepiandrosterone pour augmenter le nombre de recepteurs nmda chez un mammifere
US20030083231A1 (en) 1998-11-24 2003-05-01 Ahlem Clarence N. Blood cell deficiency treatment method
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
EP1226155B1 (fr) 1999-11-02 2007-05-02 Bayer Schering Pharma AG 18-nor-steroides utilises comme oestrogenes a effet selectif
GB0003524D0 (en) 2000-02-15 2000-04-05 Btg Int Ltd Cytoprotective steroids (II)
GB2363984A (en) 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
EP1557166A1 (fr) * 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Derives d'alpha-aminoamides pour le traitement des désordres de l'appareil urinaire inférieur

Also Published As

Publication number Publication date
SI1294382T1 (sl) 2009-02-28
EP1294382A1 (fr) 2003-03-26
HK1052300B (en) 2009-01-30
RU2003102437A (ru) 2005-01-27
EP1294382B1 (fr) 2008-07-23
CN100459980C (zh) 2009-02-11
ZA200300085B (en) 2004-04-21
NO327959B1 (no) 2009-10-26
CY1108773T1 (el) 2014-04-09
ATE401897T1 (de) 2008-08-15
NO20026243D0 (no) 2002-12-27
CZ299676B6 (cs) 2008-10-15
ES2310182T3 (es) 2009-01-01
KR100786284B1 (ko) 2007-12-18
KR20030034113A (ko) 2003-05-01
CA2414584C (fr) 2009-10-27
AU2001267709B2 (en) 2005-07-28
WO2002000225A1 (fr) 2002-01-03
PL200699B1 (pl) 2009-01-30
RU2307654C2 (ru) 2007-10-10
CN1440290A (zh) 2003-09-03
US7718639B2 (en) 2010-05-18
JP4942905B2 (ja) 2012-05-30
IL153541A0 (en) 2003-07-06
HU227152B1 (en) 2010-08-30
US20030166626A1 (en) 2003-09-04
CA2414584A1 (fr) 2002-01-03
HUP0301134A3 (en) 2006-06-28
NO20026243L (no) 2003-02-27
DE60134979D1 (de) 2008-09-04
AU6770901A (en) 2002-01-08
GB0016022D0 (en) 2000-08-23
PL359108A1 (en) 2004-08-23
JP2004501196A (ja) 2004-01-15
HUP0301134A2 (hu) 2003-08-28
HK1052300A1 (en) 2003-09-11
IL153541A (en) 2008-03-20
US20100173883A1 (en) 2010-07-08
PT1294382E (pt) 2008-10-21
GB2363983A (en) 2002-01-16
CZ200377A3 (cs) 2003-06-18

Similar Documents

Publication Publication Date Title
LU92745I2 (fr) Nétupitant/Palonosétron et leurs dérivés pharmaceutiquement acceptables (AKYNZEOr)
LU91501I2 (fr) Sugammadex et ses sels pharmaceutiquement acceptables-BRIDION
LU92517I2 (fr) Delamanide et ses dérivés pharmaceutiquement acceptables
IS2599B (is) 3-fenýlsúlfónýl-8-píperasín-1-ýl-kínólín og lyfjafræðilega viðurkenndar afleiður þess
EP1490090A4 (fr) Systemes de distribution d'agents actifs et methodes de protection et d'administration d'agents actifs
LU92871I2 (fr) Fumarate de diméthyle et ses dérivés pharmaceutiquement acceptables (tecfidera)
LU92381I2 (fr) Macitentan et ses dérivés pharmaceutiquement acceptables (OPSUMIT)
EP1626980A4 (fr) 13,24-cyclo-18,21-dinorcholanes neuroactifs et steroides pentacycliques structurellement associes
MXPA02004770A (es) Composiciones terapeuticas y metodos para su uso.
DE60032898D1 (de) Arylthiazolidindion- und aryloxazolidinderivate
DE60113112D1 (de) Neuroprotektive 7-beta-hydroxysteroide
NO20015897D0 (no) Indolylpiperidinderivater som antihistaminiske og antiallergiske midler
NO20024598L (no) Farmasöytisk aktive pyrrolidinderivater
NO20026243L (no) 7-hydroksyepiandrosteron med neurobeskyttende aktivitet
HUP0200096A3 (en) Steroid sulfatase inhibitors and using the same
IS6130A (is) Bólgueyðandi meðhöndlun fyrir bólgu tengt smit
PT1178981E (pt) 3-piridil-4-arilpirrois substituidos e metodos terapeuticos e profilacticos
DE60036356D1 (de) Düse sowie zugehöriger Absauger
AU2001291877A1 (en) N-alkoxyalkyl-substituted benzimidazoles and the use thereof as an agent againstparasitic protozoans
AU2003228305A1 (en) Pharmaceutical composition with combined active agents and methods for using the same
DE60045605D1 (de) Transformator,Lautsprechervorrichtung und Lautsprechersystem
FI991388A0 (fi) Karamurskain
TW401929U (en) Device for protecting the chair back screen from being excessively raised up and damaged
FI991103L (fi) Menetelmä ja järjestely luvattoman käytön estämiseksi langattomasti
DE50013280D1 (de) Schützanordnung